Filing Overview
Registrant: NLS Pharmaceutics Ltd., not Newcelx Ltd. as indicated in the request metadata. This Form 6-K, Report No. 2, covers October 2021 and was signed on October 26, 2021. The filing reports corporate charter amendments rather than operating or financial results.
Business Context and Reporting Period
The filing concerns the amended and restated Articles of Association filed with the commercial registry of the Canton of Nidwalden, Switzerland, on October 13, 2021. The registrant is a foreign private issuer that files annual reports on Form 20-F.
Capital Structure and Other Key Information
- Total issued share capital increased to CHF 268,155.20, represented by 13,407,760 common shares.
- Authorized share capital under Section 3(a): CHF 90,763.10, representing 4,538,155 common shares.
- Conditional share capital for employee and advisory options under Section 3(b): CHF 6,949.40, representing 347,470 common shares.
- Conditional share capital for shareholder options under Section 3(c): CHF 105,303.36, representing 5,265,168 common shares.
Financial Results and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Material Changes Versus the Prior Period
The material reported change is the filing of amended and restated Articles of Association and the related increase in issued share capital and stated authorized and conditional share capital. The filing does not provide a prior-period financial comparison.
Guidance, Risks, and Unusual Items
No management guidance, financial outlook, risk update, contingency, or unusual operating item is disclosed. The amended Articles are filed as Exhibit 3.1 and incorporated by reference.
Investor Verification Items
- Verify the registrant identity, because the filing names NLS Pharmaceutics Ltd. while the request metadata names Newcelx Ltd.
- Review Exhibit 3.1 to confirm the amended share-capital provisions and option-related conditional capital.
- Confirm the distinction between issued share capital, authorized share capital, and conditional share capital.
- Assess potential future dilution from the 347,470 employee and advisory options and 5,265,168 shareholder options.
- Obtain the company’s applicable Form 20-F or other financial filing for operating results, cash position, debt, and liquidity information.